Sangeeta Ray Banerjee
Johns Hopkins University
H-index: 41
North America-United States
Top articles of Sangeeta Ray Banerjee
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | 2024/2/27 | ||
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics | Molecules | Srikanth Boinapally Suresh Alati Zirui Jiang Yu Yan Alla Lisok | 2023/8/21 |
Preclinical development in radiopharmaceutical therapy for prostate cancer | Suresh Alati Rajan Singh Martin G Pomper Steven P Rowe Sangeeta Ray Banerjee | 2023/7/18 | |
Prostate-specific membrane antigen (PSMA) targeted multiplexed siRNA-mediated gene silencing of CD46 and PD-L1 in prostate cancer | Cancer Research | Zhihang Chen Balaji Krishnamachary Yelena Mironchik Sangeeta R Banerjee Martin G Pomper | 2022/6/15 |
A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents | Biomolecules | Ying Chen Il Minn Steven P Rowe Alla Lisok Samit Chatterjee | 2022/3/5 |
An improved 211At-labeled agent for PSMA-targeted α-therapy | Journal of Nuclear Medicine | Ronnie C Mease Choong Mo Kang Vivek Kumar Sangeeta Ray Banerjee IL Minn | 2022/2/1 |
PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer | Nanoscale | Zhihang Chen Balaji Krishnamachary Yelena Mironchik Sangeeta Ray Banerjee Martin G Pomper | 2022 |
Correction to: Hetero-bivalent agents targeting FAP and PSMA | European Journal of Nuclear Medicine and Molecular Imaging | Srikanth Boinapally Alla Lisok Gabriela Lofland Il Minn Yu Yan | 2022/11/1 |
Preclinical evaluation of 213Bi-and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer | Journal of Nuclear Medicine | Sangeeta Ray Banerjee Ala Lisok Il Minn Anders Josefsson Vivek Kumar | 2021/7/1 |
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile | Scientific reports | Srikanth Boinapally Hye-Hyun Ahn Bei Cheng Mary Brummet Hwanhee Nam | 2021/3/29 |
Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer | Nanoscale | Wojciech G Lesniak Yixuan Wu Jeeun Kang Srikanth Boinapally Sangeeta Ray Banerjee | 2021 |
Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors | Nanotheranostics | Ethel J Ngen Ying Chen Babak Behnam Azad Srikanth Boinapally Desmond Jacob | 2021 |
Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | 2021/8/3 | ||
clear cell renal cell carcinoma | Anna Caliò Diego Segala Guido Martignoni | 2020/6/19 | |
Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy | 2022/5/5 | ||
Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer | Theranostics | CJ Shen Il Minn RF Hobbs Y Chen A Josefsson | 2020/2/3 |
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer | Journal of Nuclear Medicine | Sangeeta Ray Banerjee IL Minn Vivek Kumar Anders Josefsson Ala Lisok | 2020/1/1 |
Synthesis of Two Novel Mixed Bifunctional Chelating Agents: DO2AP (tBu) 4 and DO3AP (tBu) 4 | Synlett | Fabio Travagin Luca Biondi Luciano Lattuada Giovanni B Giovenzana | 2020/8 |
Co-Authors
